Asset acquisitions.

No definition available.

Name:	mirm_AssetAcquisitionsLineItems
Namespace Prefix:	mirm_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of additional shares of equity interests issued or issuable to acquire entity.

+ References

No definition available.

+ Details

Name:	mirm_BusinessAcquisitionEquityInterestIssuedOrIssuableNumberOfAdditionalShares
Namespace Prefix:	mirm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Business acquisition future issuance of additional shares.

+ References

No definition available.

+ Details

Name:	mirm_BusinessAcquisitionFutureIssuanceOfAdditionalShares
Namespace Prefix:	mirm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical development and regulatory milestone payments payable.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayable
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon commercialization.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponCommercialization
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon initiation.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponInitiation
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Clinical development and regulatory milestone payments payable upon regulatory approval.

+ References

No definition available.

+ Details

Name:	mirm_ClinicalDevelopmentAndRegulatoryMilestonePaymentsPayableUponRegulatoryApproval
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License agreement milestone amount payable.

+ References

No definition available.

+ Details

Name:	mirm_LicenseAgreementMilestoneAmountPayable
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payment payable upon achievement of product sales.

+ References

No definition available.

+ Details

Name:	mirm_MilestonePaymentPayableUponAchievementOfProductSales
Namespace Prefix:	mirm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of product candidates.

+ References

No definition available.

+ Details

Name:	mirm_NumberOfProductCandidates
Namespace Prefix:	mirm_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty payment obligations period.

+ References

No definition available.

+ Details

Name:	mirm_RoyaltyPaymentObligationsPeriod
Namespace Prefix:	mirm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Stock issued during period shares indemnification holdback liability.

+ References

No definition available.

+ Details

Name:	mirm_StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability
Namespace Prefix:	mirm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479637/805-30-30-7

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mirm_SatiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mirm_BileAcidMedicinesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mirm_TravereTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssignmentAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mirm_LivmarliMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mirm_ShireInternationalGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=mirm_VolixibatMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mirm_AssignedLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mirm_SatiogenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mirm_SanofiAventisDeutschlandGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Acquisitions (Details)		1 Months Ended
Asset Acquisitions (Details)	Aug. 31, 2023 USD ($)	Jun. 30, 2023 shares	Jan. 31, 2023 USD ($) shares	May 31, 2022 USD ($) shares	Nov. 30, 2018 USD ($) productCandidate	Sep. 30, 2024 USD ($)	Jul. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)
Asset Acquisitions [Line Items]
Common stock issued related to the held back shares (in shares) \| shares		31,631
Satiogen
Asset Acquisitions [Line Items]
Payments for acquisition				$ 2,600,000
Total consideration				$ 24,200,000
Purchase consideration (in shares) \| shares				609,305
Additional shares of common stock issued (in shares) \| shares				32,494
Future issuance of additional common stock (in shares) \| shares			199,993	199,993
Asset Purchase Agreement \| Bile Acid Medicines \| Travere Therapeutics, Inc.
Asset Acquisitions [Line Items]
Payments for acquisition	$ 210,400,000
Product sales milestone payments, payable	$ 235,000,000.0
Shire Agreement \| Livmarli
Asset Acquisitions [Line Items]
Milestones accrued			$ 15,000,000.0				$ 10,000,000.0	$ 10,000,000.0
Shire Agreement \| Shire
Asset Acquisitions [Line Items]
Product sales milestone payments, payable					$ 30,000,000.0
Number of product candidates \| productCandidate					2
Shire Agreement \| Shire \| Livmarli
Asset Acquisitions [Line Items]
Milestone payments, payable					$ 109,500,000
Milestone payments, payable upon approval					25,000,000.0
Shire Agreement \| Shire \| Volixibat
Asset Acquisitions [Line Items]
Milestone payments, payable upon commercialization					30,000,000.0
Assigned License Agreement \| Satiogen Pharmaceuticals, Inc.
Asset Acquisitions [Line Items]
Milestone payments, payable					10,500,000
Milestone payments, payable upon approval					5,000,000.0
Milestone payments, payable upon commercialization					5,000,000.0
Milestone payments, payable upon initiation					500,000
Assigned License Agreement \| Sanofi-Aventis Deutschland GmbH
Asset Acquisitions [Line Items]
Milestone payments, payable					$ 36,000,000.0
Milestones accrued						$ 0
Royalty obligations payment period					10 years